Phase 3 Recruiting NIH
This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061977
Sites in Connecticut: - Danbury Hospital — Danbury, Connecticut
- Norwalk Hospital — Norwalk, Connecticut
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in Connecticut: - Research Site — New Haven, Connecticut
Phase 3 Recruiting Industry
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in Connecticut: - Hartford Hospital — Hartford, Connecticut
- Yale Cancer Center — New Haven, Connecticut
Phase 2 Recruiting NIH
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in Connecticut: - Connecticut Children's Medical Center — Hartford, Connecticut
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 1, Phase 2 Recruiting Industry
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…
Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Connecticut: - Yale-New Haven Hospital — New Haven, Connecticut
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Connecticut: - Yale University School of Medicine - Yale Cancer Center — New Haven, Connecticut
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carbopla…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06385080
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…
Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in Connecticut: - Hartford Hospital (site 210) — Hartford, Connecticut
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of…
Sponsor: Tubulis GmbH
NCT ID: NCT06657222
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Sponsor: GV20 Therapeutics
NCT ID: NCT05669430
Sites in Connecticut: - Yale University — New Haven, Connecticut
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P03 monotherapy in adult patients with s…
Sponsor: Alentis Therapeutics AG
NCT ID: NCT07169734
Sites in Connecticut: - Yale Comprehensive Cancer Center — New Haven, Connecticut
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 monotherapy in adult patients with s…
Sponsor: Alentis Therapeutics AG
NCT ID: NCT06747585
Sites in Connecticut: - Yale Comprehensive Cancer Center — New Haven, Connecticut
Phase 1, Phase 2 Recruiting Industry
This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatment, by IV infusion, and in combination …
Sponsor: Simcha IL-18, Inc.
NCT ID: NCT04787042
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 2 Recruiting Industry
This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment. This proof-of-concept trial will i…
Sponsor: IO Biotech
NCT ID: NCT05280314
Sites in Connecticut: - Yale — New Haven, Connecticut
Phase 2 Recruiting Industry
This will be a multi-center, randomized, open-label, parallel-group study in adult patients with head and neck cancer.
Sponsor: VSPharmTech Co.,Ltd.
NCT ID: NCT06959082
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 1 Recruiting Industry
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
Sponsor: SystImmune Inc.
NCT ID: NCT05983432
Sites in Connecticut: - Yale University, Yale Cancer Center — New Haven, Connecticut
Phase 1 Recruiting Industry
This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
Sponsor: Normunity AccelCo, Inc.
NCT ID: NCT07182149
Sites in Connecticut: - Normunity Investigational Site — New Haven, Connecticut
Phase 1 Recruiting Industry
The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have been ineligib…
Sponsor: EvolveImmune United, Inc
NCT ID: NCT07217171
Sites in Connecticut: - Yale University Cancer Center — New Haven, Connecticut
Phase 1 Recruiting Industry
The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (…
Sponsor: Calico Life Sciences LLC
NCT ID: NCT04777994
Sites in Connecticut: - Yale University School of Medicine /ID# 225707 — New Haven, Connecticut
Phase 1 Recruiting Industry
Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid…
Sponsor: Adcendo ApS
NCT ID: NCT06597721
Sites in Connecticut: - Yale University Cancer Center — New Haven, Connecticut
Phase 1 Recruiting Industry
This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unrese…
Sponsor: Immunome, Inc.
NCT ID: NCT07578571
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 1 Recruiting Industry
The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expr…
Sponsor: EMD Serono Research & Development Institute, Inc.
NCT ID: NCT07360314
Sites in Connecticut: - Yale University - Yale University School of Medicine — New Haven, Connecticut
Phase 1 Recruiting Industry
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
Sponsor: Kivu Bioscience Inc.
NCT ID: NCT07229313
Sites in Connecticut: - Kivu Trial Site — New Have, Connecticut
NA Recruiting Network
This is a randomized controlled trial to compare survival for patients who undergoe robotic assisted laparoscopy versus open hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.
Sponsor: GOG Foundation
NCT ID: NCT04831580
Sites in Connecticut: - Hartford Hospital — Hartford, Connecticut
- Hartford Healthcare Cancer Institute at Hartford Hospital — Hartford, Connecticut
- Hartford Healthcare Medical Group-Manchester — Manchester, Connecticut
- Harford HealthCare Cancer Institute at the Hospital of Central Connecticut — New Britain, Connecticut